Shc protein-related methods and compositions for the prognosis of breast, prostate and ovarian cancer
View Patent ↗This invention provides methods for determining whether a breast, prostate or ovarian tumor or tumor cell is aggressive, based on the quantitative measurement of p66-Shc and phosphorylated Shc. This invention also provides related methods of determining the likelihood of tumor recurrence. This invention further provides a method for determining whether a tumor can be successfully treated using a tyrosine kinase inhibitor. Finally, this invention provides antibodies and kits for practicing the instant methods.
1. A method of determining, for a subject diagnosed as afflicted with a breast tumor, the likelihood of the subject suffering a recurrence of the tumor following primary treatment, which method comprises determining the amount of p66-She and/or phosphorylated Shc present in the cancerous cells of the tumor, and comparing the amount so determined to a standard, wherein the standard comprises the amount of p66-She and/or phosphorylated Shc present in the cancerous cells of a tumor from a subject with no recurrence of the tumor, and wherein low levels of p66-Shc compared to the levels of p66-She in the standard, high levels of phosphorylated Shc compared to the levels of phosphorylated Shc in the standard, and/or low levels of p66-Shc coupled with high levels of phosphorylated Shc compared to the levels of p66-Shc coupled with the levels of phosphorylated Shc in the standard indicates that the subject will suffer a recurrence of the tumor, thereby determining the likelihood of recurrence.
2. A method for determining, for a subject diagnosed as afflicted with a breast tumor, the likelihood of the subject suffering a recurrence of the tumor following primary treatment, which method comprises determining the ratio of p66-Shc to phosphorylated Shc and/or the ratio of phosphorylated Shc to p66-Shc present in the cancerous cells of the tumor, and comparing the ratio(s) so determined to a standard, wherein the standard comprises the amount of p66-Shc and/or phosphorylated Shc present in the cancerous cells of a tumor from a subject with no recurrence of the tumor, and wherein low levels of p66-Shc coupled with high levels of phosphorylated Shc compared to the levels of p66-Shc coupled with the levels of phosphorylated Shc in the standard indicates that the subject will suffer a recurrence of the tumor thereby determining the likelihood of recurrence.
3. A method for determining, for a subject diagnosed as afflicted with a breast tumor, the likelihood of the subject suffering a recurrence of the tumor following primary treatment, which method comprises determining the amounts of p66-Shc and/or phosphorylated Shc in each of a plurality of cancerous cells present in the tumor, and comparing the amounts so determined with a standard, wherein the standard comprises the amount of p66-Shc and/or phosphorylated Shc present in the cancerous cells of a tumor from a subject with no recurrence of the tumor, and wherein low levels of p66-Shc compared to the levels of p66-Shc in the standard, high levels of phosphorylated Shc compared to the levels of phosphorylated Shc in the standard, and/or low levels of p66-Shc coupled with high levels of phosphorylated Shc compared to the levels of p66-Shc coupled with the levels of phosphorylated Shc in the standard indicates that the subject will suffer a recurrence of the tumor thereby determining the likelihood of recurrence.
4. A method for determining, for a subject diagnosed as afflicted with a breast tumor, the likelihood of the subject suffering a recurrence of the tumor following primary treatment, which method comprises determining the ratios of p66-Shc to phosphorylated Shc and/or the ratios of phosphorylated She to p66-Shc in each of a plurality of cancerous cells present in the tumor, and comparing the ratios so determined with a standard, wherein the standard comprises the amount of p66-She and/or phosphorylated Shc present in the cancerous cells of a tumor from a subject with no recurrence of the tumor, and wherein low levels of p66-She coupled with high levels of phosphorylated Shc compared to the levels of p66-Shc coupled with the levels of phosphorylated Shc in the standard indicates that the subject will suffer a recurrence of the tumor thereby determining the likelihood of recurrence.
5. The method of claim 3 wherein the subject is human.
6. The method of claim 3 wherein the subject's lymph nodes are free of tumor cells.
7. The method of claim 3 wherein a detectable antibody that specifically binds to p66-Shc, a detectable antibody that specifically binds to phosphorylated Shc, flow cytometry, immunohistochemistry or a combination thereof is used to determine the amounts of p66-Shc or phosphorylated Shc.
8. The method of claim 3 wherein the tumor cell is present in a tissue sample.
9. The method of claim 3 wherein the primary treatment comprises a treatment selected from the group consisting of surgery, radiation, hormone therapy and chemotherapy.
10. The method of claim 1 , wherein only the amount of p66-Shc is determined.
11. The method of claim 1 , wherein only the amount of phosphorylated Shc is determined.
12. The method of claim 1 , wherein the amounts of both p66-Shc and phosphorylated Shc are determined.
13. The method of claim 1 wherein the subject is human.
14. The method of claim 2 wherein the subject is human.
15. The method of claim 4 wherein the subject is human.
16. The method of claim 1 wherein the subject's lymph nodes are free of tumor cells.
17. The method of claim 2 wherein the subject's lymph nodes are free of tumor cells.
18. The method of claim 4 wherein the subject's lymph nodes are free of tumor cells.
19. The method of claim 1 wherein a detectable antibody that specifically binds to p66-Shc, a detectable antibody that specifically binds to phosphorylated Shc, flow cytometry, immunohistochemistry or a combination thereof is used to determine the amounts of p66-Shc and phosphorylated Shc.
20. The method of claim 2 wherein a detectable antibody that specifically binds to p66-Shc, a detectable antibody that specifically binds to phosphorylated Shc, flow cytometry, immunohistochemistry or a combination thereof is used to determine the amounts of p66-She and phosphorylated Shc.
21. The method of claim 4 wherein the determination step is selected from the group consisting of: the use of a detectable antibody that specifically binds to p66-Shc, the use of a detectable antibody that specifically binds phosphorylated Shc, the use of flow cytometry, the use of immunohistochemistry and a combination thereof.
22. The method of claim 1 wherein the tumor cell is present in a tissue sample.
23. The method of claim 2 wherein the tumor cell is present in a tissue sample.
24. The method of claim 4 wherein the tumor cell is present in a tissue sample.
25. The method of claim 1 wherein the primary treatment comprises a treatment selected from the group consisting of surgery, radiation, hormone therapy and chemotherapy.
26. The method of claim 2 wherein the primary treatment comprises a treatment selected from the group consisting of surgery, radiation, hormone therapy and chemotherapy.
27. The method of claim 4 wherein the primary treatment comprises a treatment selected from the group consisting of surgery, radiation, hormone therapy and chemotherapy.